|Bid||0.00 x 900|
|Ask||0.00 x 1800|
|Day's Range||15.32 - 15.69|
|52 Week Range||9.25 - 23.85|
|Beta (5Y Monthly)||1.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 08, 2021 - Nov 12, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||37.43|
Omeros (OMER) delivered earnings and revenue surprises of 20.00% and 11.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
SEATTLE, August 09, 2021--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced recent highlights and developments as well as financial results for the second quarter ended June 30,
SEATTLE, August 03, 2021--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2021, on Monday, August 9, 2021, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.